Prestige Consumer Healthcare (NYSE:PBH) Downgraded to "Strong Sell" Rating by Zacks Research

Key Points

• Prestige Consumer Healthcare has been downgraded from a "hold" rating to a "strong sell" rating by Zacks Research, indicating a significant negative shift in analyst sentiment.
• The company's stock has dropped 2.5%, currently trading around $65.06, with a consensus target price of $93.33 according to MarketBeat.com.
• Recently reported quarterly earnings missed expectations, with earnings per share (EPS) of $0.95 compared to the consensus estimate of $1.01, contributing to a decline in revenue of 6.6% year-over-year.

Zacks Research lowered shares of Prestige Consumer Healthcare (NYSE:PBH - Free Report) from a hold rating to a strong sell rating in a research report released on Thursday morning,Zacks.com reports.

PBH has been the topic of several other research reports. Canaccord Genuity Group reduced their price target on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen cut shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $93.33.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock traded up $0.63 on Thursday, hitting $65.68. 729,115 shares of the company traded hands, compared to its average volume of 613,028. The business has a 50-day simple moving average of $71.75 and a 200 day simple moving average of $79.73. Prestige Consumer Healthcare has a 52 week low of $62.95 and a 52 week high of $90.04. The stock has a market capitalization of $3.23 billion, a P/E ratio of 15.42, a price-to-earnings-growth ratio of 2.06 and a beta of 0.46. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business had revenue of $249.53 million during the quarter, compared to the consensus estimate of $260.71 million. During the same quarter in the prior year, the firm posted $0.90 EPS. The company's revenue for the quarter was down 6.6% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Research analysts expect that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. UMB Bank n.a. increased its position in Prestige Consumer Healthcare by 81.8% during the second quarter. UMB Bank n.a. now owns 320 shares of the company's stock valued at $26,000 after acquiring an additional 144 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in Prestige Consumer Healthcare by 312.5% during the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company's stock valued at $26,000 after acquiring an additional 250 shares during the last quarter. Maseco LLP purchased a new stake in shares of Prestige Consumer Healthcare during the second quarter valued at $27,000. Opal Wealth Advisors LLC purchased a new stake in shares of Prestige Consumer Healthcare during the first quarter valued at $38,000. Finally, Elevation Point Wealth Partners LLC purchased a new stake in shares of Prestige Consumer Healthcare during the second quarter valued at $46,000. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.